Lancet Respiratory Medicine

Article	Citations
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study	6840
Pathological findings of COVID-19 associated with acute respiratory distress syndrome	6092
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?	1987
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations	1043
Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017	996
Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans	909
COVID-19 cytokine storm: the interplay between inflammation and coagulation	907
Rational use of face masks in the COVID-19 pandemic	890
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy	737
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes	633
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study	585
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study	476
COVID-19 and the impact of social determinants of health	467
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial	460
3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study	432
Management of acute kidney injury in patients with COVID-19	430
Particle sizes of infectious aerosols: implications for infection control	411
Sex difference and smoking predisposition in patients with COVID-19	406
SARS-CoV-2 viral load predicts COVID-19 mortality	406
Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures	394
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study	386
Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases	378
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	369
Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study	357
Pulmonary fibrosis secondary to COVID-19: a call to arms?	356

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	356
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity	352
Evidence mounts on the disproportionate effect of COVID-19 on ethnic minorities	348
COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?	348
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial	342
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study	327
Human recombinant soluble ACE2 in severe COVID-19	326
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial	324
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controll	318
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19	316
Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study	307
NICE guideline on long COVID	300
Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society	283
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?	279
Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission	276
New variant of SARS-CoV-2 in UK causes surge of COVID-19	276
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance	274
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers	273
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study	269
Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data	268
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial	267
Staff safety during emergency airway management for COVID-19 in Hong Kong	260
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials	255
False-positive COVID-19 results: hidden problems and costs	254
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial	253
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicent	253
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial	250
Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a rand	248
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study	238
COVID-19: a heavy toll on health-care workers	233
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial	229
COVID-19 outbreak: less stethoscope, more ultrasound	229
Treatment for severe acute respiratory distress syndrome from COVID-19	216
Omicron variant and booster COVID-19 vaccines	209
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	199
COVID-19, ECMO, and lymphopenia: a word of caution	198
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial	198
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform	198
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities	195
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	191
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	183
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial	182
Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses	181
Understanding pathways to death in patients with COVID-19	176
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study	175
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study	174
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial	170
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, contr	168
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study	168
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries	167

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an ope	159
Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study	159
Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?	154
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study	151
SARS-CoV-2 evolution and vaccines: cause for concern?	148
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis	148
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study	142
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial	138
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controll	137
Decreasing antibiotic use, the gut microbiota, and asthma incidence in children: evidence from population-based and prospective cohort studies	134
Respiratory support for patients with COVID-19 infection	134
Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study	133
Immunomodulation in COVID-19	133
Chronic respiratory diseases: a global view	131
Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial	129
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	128
SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study	125
Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial	122
Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis	121
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment	121
Tobacco smoking and COVID-19 infection	120
Interleukin-6: obstacles to targeting a complex cytokine in critical illness	119
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation	117
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial	117
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial	116
Subphenotypes in critical care: translation into clinical practice	116
Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19	115
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study	114
COVID-19 infection in children	114
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Character	111
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?	108
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-labe	106
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study	105
COVID-19 transmission—up in the air	104
Impact of COVID-19 on people with cystic fibrosis	104
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	103
The Russian vaccine for COVID-19	102
Respiratory health in athletes: facing the COVID-19 challenge	102
Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study	102
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled pha	101
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial	101
Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient	101
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities	101
Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data	101
Immunotherapies for COVID-19: lessons learned from sepsis	101
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (AND	100
Implications of the second wave of COVID-19 in India	99
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	99
Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study	99
The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions	98
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study	98
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study	97
Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis	97
Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study	96
Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database	96
Major differences in ICU admissions during the first and second COVID-19 wave in Germany	96
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan	96
The genetics of asthma and the promise of genomics-guided drug target discovery	96
Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a random	94
Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties	93
Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study	93
Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study	91
Physical distancing in schools for SARS-CoV-2 and the resurgence of rhinovirus	91
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors	89
When to consider lung transplantation for COVID-19	89
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial	87
Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base	86
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial	86
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial	85
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controll	84
GOLD COPD report: 2023 update	83
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context	83
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019	83
Advancing precision medicine for acute respiratory distress syndrome	83
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	82
Lifting of COVID-19 restrictions in the UK and the Delta variant	81
Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study	81
Saliva as a gold-standard sample for SARS-CoV-2 detection	81
Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial	81
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease	81

Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial	80
Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort	79
Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase	79
Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial	77
Monitoring the COVID-19 epidemic in the context of widespread local transmission	77
The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?	77
Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study	76
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	76
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study	75
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled	75
Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks	74
Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study	74
Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study	74
Adoption of COVID-19 triage strategies for low-income settings	74
Corticosteroids for COVID-19: the search for an optimum duration of therapy	74
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	74
Advances in understanding and reducing the burden of severe asthma in children	74
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	72
COVID-19: the need for continuous medical education and training	72
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK	71
COVID-19 among people experiencing homelessness in England: a modelling study	71
Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December,	70
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	70
Awake prone positioning for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure: a systematic review and meta-analysis	70
Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts	70
The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study	70
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	69
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, doubl	69
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations	69
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial	69
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials	69
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial	68
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials	68
Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management	68
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial	67
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts	67
Challenges in lung cancer therapy during the COVID-19 pandemic	67
Variations in end-of-life practices in intensive care units worldwide (Ethicus-2): a prospective observational study	67
The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions	66
COVID-19 in Nigeria: a disease of hunger	65
The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysis	65
Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study	65
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study	64
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	64
Antihypertensive drugs and risk of COVID-19?	64
Long COVID: aiming for a consensus	64
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials	63
Use of non-invasive ventilation for patients with COVID-19: a cause for concern?	63
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial	63
SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors	63
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	62
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial	61
The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study	61
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study	61
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised	60
Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study	60
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial	60
Use of facemasks during the COVID-19 pandemic	60
Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis	60
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	60
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial	59
Continuous positive airway pressure versus standard care for the treatment of people with mild obstructive sleep apnoea (MERGE): a multicentre, randomised controlled trial	59
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	58
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study	58
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	58
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	57
Prevalence, risk factors, and clinical implications of preserved ratio impaired spirometry: a UK Biobank cohort analysis	57
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities	57
Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine	56
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion	56
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers	56
Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort diagnostic accuracy study	55
COVID-19 hospital admissions: Brazil's first and second waves compared	55
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: resul	54
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial	53
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study	53
Delayed-onset myocarditis following COVID-19	52
Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making?	52
Immunomodulation by macrolides: therapeutic potential for critical care	52
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 tri	52
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	51
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial	51
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study	51
Dynamic zero COVID policy in the fight against COVID	51
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label	51
Lung function testing in the COVID-19 endemic	51
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study	50
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	50
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, ran	50
Efforts escalate to protect homeless people from COVID-19 in UK	49
Extracorporeal membrane oxygenation for COVID-19 during first and second waves	49
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems	48
Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study	48
A 5-point strategy for improved connection with relatives of critically ill patients with COVID-19	48
Inhaled isoflurane via the anaesthetic conserving device versus propofol for sedation of invasively ventilated patients in intensive care units in Germany and Slovenia: an open-label, phase 3, randomi	47